Early clinical trials assessing other drugs targeting the epigenetic mechanisms indicated above, specifically non-selective histone deacetylases (panobinostat, vorinostat, pracinostat) [114–116] and one inhibitor of LSD1 (GSK2879552), showed minimal efficacy in early clinical trials assessing relapsed or refractory AML [117]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.